$0.051

Want access to our research and new buy ideas?

Take a free 15 day trial - no credit card required.

Start your free trial now

General Information

Actinogen Medical Limited
ACW
http://www.actinogen.com.au
Biotechnology
32
620

Current Price Data+

Current Price $0.051
Open $0.051
High $0.051
Low $0.051
Last Close $0.051
Volume 185984
Price Movement - ( No change )
  • +Security prices are delayed by at least 20 minutes and are indicative only.

Company Overview

Business Description

Actinogen Medical Limited (ACW, formerly Actinogen Limited) is focused on the treatment of Alzheimer's Disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious conditions of Alzheimer's and dementia. It is developing a novel drug to treat the condition and other age-related neurodegenerative diseases. Xanamem is a lead product of Actinogen for the treatment of Alzheimer.

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016 A -3.6 -0.6 0.0% 0.0 0.0 0.0% 0.0%
2015 A -5.4 -1.3 0.0% 0.0 0.0 0.0% 0.0%
2014 A -0.4 -0.3 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2014 A 2015 A 2016 A 2014 A 2015 A 2016 A 2014 A 2015 A 2016 A
Actinogen Medical (ACW) $32M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
CSL (CSL) $63,680M 0.2288 0.1894 0.1818 36.9243 31.0452 26.2701 1.44% 1.41% 1.67%
Mesoblast (MSB) $579M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Monash IVF Group (MVF) $370M 0.0000 0.0000 0.0715 0.0000 12.2084 11.3933 0.00% 5.73% 6.14%
Sirtex Medical (SRX) $804M 0.2975 -0.1444 0.0682 11.6526 13.6186 12.7492 2.15% 2.70% 2.87%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 0.00 0.00
Market 1.03 15.50 1.55 1.18
Sector 0.92 12.40 4.00 1.83

Directors

Name Position Start Date
Dr John (Bill) William Ketelbey Chief Executive Officer, Managing Director 18 Dec 2014
Dr Geoffrey E.D Brooke Non-Executive Chairman, Non-Executive Director 1 Mar 2017
Dr Jason Loveridge Non-Executive Director 1 Dec 2014

Management

Name Position
Peter Webse Company Secretary
Vincent Ruffles Vice President of Clinical Research

Substantial Shareholders

Holding Name
48,147,864 (7.94%) Edinburgh Technology Fund Limited
36,250,000 (5.98%) Martin Rogers
34,717,184 (5.72%) Tisia Nominees P/L
34,717,184 (5.72%) J K Holdings Pty Ltd

Calendar of Events

Date Event
22 October 2018 Report (Annual)
17 August 2018 Report (Annual)
17 August 2018 Report (Prelim)
26 February 2018 Report (Interim)
29 November 2017 AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.